Clinical Trials Logo
  1. Home
  2. MSS
  3. NCT03271047

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

MSS Clinical Trial

Official title:
An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Clinical Trial Summary

This is a multicenter, open-label, Phase 1B/2 study to evaluate the safety and assess the preliminary anti-tumor activity of binimetinib administered in combination with nivolumab or nivolumab + ipilimumab in adult patients with advanced metastatic colorectal cancer (mCRC) with microsatellite stable (MSS) disease and presence of a RAS mutation that have received at least one prior line of therapy and no more than 2 prior lines of therapy. The study contains a Phase 1b period to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and schedule of binimetinib followed by a randomized Phase 2 period to assess the efficacy of the combinations.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03271047
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date October 18, 2017
Completion date February 25, 2021
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04527068 - QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer Phase 2
Recruiting NCT04659382 - Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer Phase 2
Recruiting NCT05815303 - XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer Phase 2
Recruiting NCT06321081 - ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC Phase 2
Active, not recruiting NCT05733611 - RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC Phase 2
Recruiting NCT04483219 - Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. Phase 2
Active, not recruiting NCT04046445 - Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer Phase 1
Recruiting NCT04030260 - Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer Phase 2
Recruiting NCT05877573 - Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer N/A
Recruiting NCT06199232 - Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment N/A
Recruiting NCT05731726 - Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT05933980 - Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer Phase 2
Completed NCT03274804 - Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC Phase 1